Cancer-associated fibroblasts: from basic science to anticancer therapy

참고문헌 (107)

1. Chen, Y., "Clinical and therapeutic relevance of cancer-associated fibroblasts", Nat. Rev. Clin. Oncol, 18, pp.792~804 (2021)
2. Raghavan, S., "Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer", Cell, 184, pp.6119~6137 (2021)
3. Kalluri, R., "The biology and function of fibroblasts in cancer", Nat. Rev. Cancer, 16, pp.582~598 (2016)
4. Yoshida, G. J, "Regulation of heterogeneous cancer-associated fibroblasts : the molecular pathology of activated signaling pathways", J. Exp. Clin. Cancer Res, 39, pp.112~ (2020)
5. Rhim, A. D., "Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma", Cancer Cell, 25, pp.735~747 (2014)
6. Ozdemir, B. C., "Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival", Cancer Cell, 25, pp.719~734 (2014)
7. Ohlund, D., "Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer", J. Exp. Med, 214, pp.579~596 (2017)
8. Elyada, E., "Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts", Cancer Discov, 9, pp.1102~1123 (2019)
9. Bernard, V., "Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression", Clin. Cancer Res, 25, pp.2194~2205 (2019)
10. Ligorio, M., "Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer", Cell, 178, pp.160~175 (2019)
11. Gabbiani, G., "Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction", Experientia, 27, pp.549~550 (1971)
12. Micallef, L., "The myofibroblast, multiple origins for major roles in normal and pathological tissue repair", Fibrogenes. Tissue Repair, 5, pp.S5~ (2012)
13. Simian, M., "The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells", Development, 128, pp.3117~3131 (2001)
14. Tomasek, J. J., "Myofibroblasts and mechano-regulation of connective tissue remodelling", Nat. Rev. Mol. Cell Biol, 3, pp.349~363 (2002)
15. Koliaraki, V., "The mesenchymal context in inflammation, immunity and cancer", Nat. Immunol, 21, pp.974~982 (2020)
16. Dvorak, H. F., "Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing", N. Engl. J. Med, 315, pp.1650~1659 (1986)
17. Braidotti, N., "Piezo1 channel as a potential target for hindering cardiac fibrotic remodeling", Int. J. Mol. Sci, 23, pp.8065~ (2022)
18. Kahounova, Z., "The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelialto-mesenchymal transition", Cytometry A, 93, pp.941~951 (2018)
19. Sahai, E., "A framework for advancing our understanding of cancerassociated fibroblasts", Nat. Rev. Cancer, 20, pp.174~186 (2020)
20. Bartoschek, M., "Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing", Nat. Commun, 9, pp.5150~ (2018)
21. Nguyen, E. V., "Proteomic profiling of human prostate cancer-associated fibroblasts(CAF)reveals LOXL2-dependent regulation of the tumor microenvironment", Mol. Cell Proteom, 18, pp.1410~1427 (2019)
22. Zeltz, C., "alpha11beta1 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration", Cancers(Basel), 11, pp.765~ (2019)
23. Guido, C., "Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth : connecting TGF-beta signaling with"Warburglike"cancer metabolism and L-lactate production", Cell Cycle, 11, pp.3019~3035 (2012)
24. Goetz, J. G., "Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis", Cell, 146, pp.148~163 (2011)
25. Armulik, A., "Pericytes : developmental, physiological, and pathological perspectives, problems, and promises", Dev. Cell, 21, pp.193~215 (2011)
26. Arnold, J. N., "Tumoral immune suppression by macrophages expressing fibroblast activation protein-alpha and heme oxygenase-1", Cancer Immunol. Res, 2, pp.121~126 (2014)
27. Kim, D., "Identification and characterization of cancer-associated fibroblast subpopulations in lung adenocarcinoma", Cancers(Basel), 14, pp.3486~ (2022)
28. Venning, F. A., "Deciphering the temporal heterogeneity of cancerassociated fibroblast subpopulations in breast cancer", J. Exp. Clin. Cancer Res, 40, pp.175~ (2021)
29. Sebastian, A., "Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer", Cancers(Basel), 12, pp.1307~ (2020)
30. Vonlaufen, A., "Pancreatic stellate cells : partners in crime with pancreatic cancer cells", Cancer Res, 68, pp.2085~2093 (2008)
31. Ezhilarasan, D., "Hepatic stellate cells in the injured liver : perspectives beyond hepatic fibrosis", J. Cell Physiol, 237, pp.436~449 (2022)
32. Heinemann, V., "Tumour-stroma interactions in pancreatic ductal adenocarcinoma : rationale and current evidence for new therapeutic strategies", Cancer Treat. Rev, 40, pp.118~128 (2014)
33. Valkenburg, K. C., "Targeting the tumour stroma to improve cancer therapy", Nat. Rev. Clin. Oncol, 15, pp.366~381 (2018)
34. Sperb, N., "Crosstalk between tumor and stromal cells in pancreatic ductal adenocarcinoma", Int. J. Mol. Sci, 21, pp.5486~ (2020)
35. Schoepp, M., "Dysregulation of miRNA expression in cancer associated fibroblasts(CAFs)and its consequences on the tumor microenvironment", Cancers(Basel), 9, pp.54~ (2017)
36. Helms, E. J., "Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts", Cancer Discov, 12, pp.484~501 (2022)
37. Dominguez, C. X., "Single-cell RNA sequencing reveals stromal evolution into LRRC15(+)myofibroblasts as a determinant of patient response to cancer immunotherapy", Cancer Discov, 10, pp.232~253 (2020)
38. Kobayashi, H., "The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis", Gastroenterology, 162, pp.890~906 (2022)
39. Plikus, M. V., "Fibroblasts : Origins, definitions, and functions in health and disease", Cell, 184, pp.3852~3872 (2021)
40. Garcia, P. E., "Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma", Cell Mol. Gastroenterol. Hepatol, 10, pp.581~599 (2020)
41. Kalluri, R., "Fibroblasts in cancer", Nat. Rev. Cancer, 6, pp.392~401 (2006)
42. Bochet, L., "Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer", Cancer Res, 73, pp.5657~5668 (2013)
43. Hosaka, K., "Pericyte-fibroblast transition promotes tumor growth and metastasis", Proc. Natl Acad. Sci. USA, 113, pp.E5618~E5627 (2016)
44. Rynne-Vidal, A., "The mesothelial origin of carcinoma associated-fibroblasts in peritoneal metastasis", Cancers(Basel), 7, pp.1994~2011 (2015)
45. McAnulty, R. J., "Fibroblasts and myofibroblasts: their source, function and role in disease", Int. J. Biochem. Cell Biol, 39, pp.666~671 (2007)
46. Arina, A., "Tumor-associated fibroblasts predominantly come from local and not circulating precursors", Proc. Natl Acad. Sci. USA, 113, pp.7551~7556 (2016)
47. Worthley, D. L., "Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation", Stem Cells, 27, pp.1463~1468 (2009)
48. Kurashige, M., "Origin of cancer-associated fibroblasts and tumor-associated macrophages in humans after sex-mismatched bone marrow transplantation", Commun. Biol, 1, pp.131~ (2018)
49. Direkze, N. C., "Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts", Cancer Res, 64, pp.8492~8495 (2004)
50. Raz, Y., "Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer", J. Exp. Med, 215, pp.3075~3093 (2018)
51. Barcellos-de-Souza, P., "Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironmentderived TGF-beta1", Stem Cells, 34, pp.2536~2547 (2016)
52. Weber, C. E., "Osteopontin mediates an MZF1-TGF-beta1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer", Oncogene, 34, pp.4821~4833 (2015)
53. Iwamoto, C., "Bone marrow-derived macrophages converted into cancerassociated fibroblast-like cells promote pancreatic cancer progression", Cancer Lett, 512, pp.15~27 (2021)
54. Vierhout, M., "Monocyte and macrophage derived myofibroblasts : Is it fate? A review of the current evidence", Wound Repair Regen, 29, pp.548~562 (2021)
55. Tang, P. C., "Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition", Adv. Sci. (Weinh.), 9, pp.e2101235~ (2022)
56. Neuzillet, C., "Inter-and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma", J. Pathol, 248, pp.51~65 (2019)
57. Tran, L. L., "ELF3 mediates IL-1alpha induced differentiation of mesenchymal stem cells to inflammatory iCAFs", Stem Cells, 39, pp.1766~1777 (2021)
58. Bhattacharjee, S., "Tumor restriction by type I collagen opposes tumorpromoting effects of cancer-associated fibroblasts", J. Clin. Invest, 131 (2021)
59. Zhang, X., "Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair", Oncogene, 41, pp.2372~2389 (2022)
60. Affo, S., "Promotion of cholangiocarcinoma growth by diverse cancerassociated fibroblast subpopulations", Cancer Cell, 39, pp.866~882 (2021)
61. Costa, A., "Fibroblast heterogeneity and immunosuppressive environment in human breast cancer", Cancer Cell, 33, pp.463~479 (2018)
62. Huang, H., "Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer", Cancer Cell, 40, pp.656~673 (2022)
63. Kerdidani, D., "Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts", J. Exp. Med, 219, pp.e20210815~ (2022)
64. Aoki, S., "Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma", Gut, 71, pp.185~193 (2022)
65. Buechler, M. B., "Cross-tissue organization of the fibroblast lineage", Nature, 593, pp.575~579 (2021)
66. Krishnamurty, A. T., "LRRC15(+)myofibroblasts dictate the stromal setpoint to suppress tumour immunity", Nature, 611, pp.148~154 (2022)
67. Su, S., "CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness", Cell, 172, pp.841~856 (2018)
68. Santi, A., "Cancer associated fibroblasts : the architects of stroma remodeling", Proteomics, 18, pp.e1700167~ (2018)
69. Biffi, G., "IL1-induced JAK", STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma, 2019, pp.9, 282~301
70. Wormann, S. M., "Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival", Gastroenterology, 151, pp.180~193 (2016)
71. Vennin, C., "CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan", Nat. Commun, 10, pp.3637~ (2019)
72. Novo, D., "Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels", Nat. Commun, 9, pp.5069~ (2018)
73. Lawrence, M. G., "Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer", Clin. Epigenetics, 12, pp.48~ (2020)
74. Pidsley, R., "Enduring epigenetic landmarks define the cancer microenvironment", Genome Res, 28, pp.625~638 (2018)
75. Nash, C., "Genome-wide analysis of AR binding and comparison with transcript expression in primary human fetal prostate fibroblasts and cancer associated fibroblasts", Mol. Cell Endocrinol, 471, pp.1~14 (2018)
76. Lee, Y. T, "Cancer-associated fibroblasts: epigenetic regulation and therapeutic intervention in breast cancer", Cancers (Basel), 12, pp.2949~ (2020)
77. Ippolito, L., "Lactate rewires lipid metabolism and sustains a metabolicepigenetic axis in prostate cancer", Cancer Res, 82, pp.1267~1282 (2022)
78. Xiao, Q., "Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation", Cancer Res, 76, pp.5395~5404 (2016)
79. Eckert, M. A., "Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts", Nature, 569, pp.723~728 (2019)
80. Kay, E. J., "Cancer-associated fibroblasts require proline synthesis by PYCR1for the deposition of pro-tumorigenic extracellular matrix", Nat. Metab, 4, pp.693~710 (2022)
81. Pan, X., "Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma", J. Hematol. Oncol, 14, pp.184~ (2021)
82. Pavlides, S., "The reverse Warburg effect : aerobic glycolysis in cancer associated fibroblasts and the tumor stroma", Cell Cycle, 8, pp.3984~4001 (2009)
83. Becker, L. M., "Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer", Cell Rep, 31, pp.107701~ (2020)
84. Zhang, D., "Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation", Cell Rep, 10, pp.1335~1348 (2015)
85. Shim, H., "c-Myc transactivation of LDH-A : implications for tumor metabolism and growth", Proc. Natl Acad. Sci. USA, 94, pp.6658~6663 (1997)
86. Cui, J., "FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression", Clin. Cancer Res, 20, pp.2595~2606 (2014)
87. Martinez-Ordonez, A., "POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation", Oncogene, 40, pp.2725~2740 (2021)
88. Lee, K. W., "PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression", Nat. Commun, 13, pp.2793~ (2022)
89. Linares, J. F., "The lactate-NAD(+)axis activates cancer-associated fibroblasts by downregulating p62", Cell Rep, 39, pp.110792~ (2022)
90. Kogure, A., "Cancer cells with high-metastatic potential promote a glycolytic shift in activated fibroblasts", PLoS One, 15, pp.e0234613~ (2020)
91. McAndrews, K. M., "Identification of functional heterogeneity of carcinomaassociated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer", Cancer Disco, 12, pp.1580~1597 (2022)
92. Hofheinz, R. D., "Stromal antigen targeting by a humanised monoclonal antibody : an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer", Onkologie, 26, pp.44~48 (2003)
93. Peran, I., "Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice", Gastroenterology, 160, pp.1359~1372 (2021)
94. Incio, J., "Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy", Cancer Discov, 6, pp.852~869 (2016)
95. Kim, D. K., "PD-L1-directed PlGF", VEGF blockade synergizes with chemotherapy by targeting CD141(+)cancer-associated fibroblasts in pancreatic cancer, 2022, pp.13, 6292~
96. Lee, D. H., "Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities", Biomaterials, 171, pp.34~45 (2018)
97. Laklai, H., "Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression", Nat. Med, 22, pp.497~505 (2016)
98. Hu, H., "Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms", Cancer Cell, 39, pp.1531~1547 (2021)
99. Arteaga, C. L., "Treatment of HER2-positive breast cancer : current status and future perspectives", Nat. Rev. Clin. Oncol, 9, pp.16~32 (2011)
100. Liu, X., "CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition", Cancer Cell, 40, pp.1341~1357 (2022)
101. Zhuang, Z., "IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation", Clin. Cancer Res, 22, pp.1432~1444 (2016)
102. Gaspar, N., "Phase I", II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma(ITCC-050)(☆), 2021, pp.6, 100250~
103. Feng, J., "SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGFbeta, for recurrent or metastatic cervical cancer : a clinical expansion cohort of a phase I study", Clin. Cancer Res, 28, pp.5297~5305 (2022)
104. Strauss, J., "Phase I Trial of M7824(MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors", Clin. Cancer Res, 24, pp.1287~1295 (2018)
105. Bibeau, K., "Progression-free survival in patients with cholangiocarcinoma with or without FGF", FGFR alterations : a FIGHT-202 post hoc analysis of prior systemic therapy response, 2022, pp.6, e2100414~
106. Dorff, T. B., "Clinical and correlative results of SWOG S0354 : a phase II trial of CNTO328(siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer", Clin. Cancer Res, 16, pp.3028~3034 (2010)
107. Roswall, P., "Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling", Nat. Med, 24, pp.463~473 (2018)

관련 논문AI추천